ALAMEDA, Calif.--(BUSINESS WIRE)--OncoCyte Corporation (“OncoCyte”), a company focused on non-invasive cancer diagnostics, announced the appointment of Dr. Andrew J. Last as an independent member of OncoCyte’s Board of Directors. Dr. Last is currently the Executive Vice President & Chief Operating Officer at Affymetrix, a pioneer in microarray technology and a leader in genomics analysis, and previously held a number of leadership positions in global healthcare and life science. Dr. Last will also serve on OncoCyte’s Audit Committee. OncoCyte previously announced that it plans to be the third member of the BioTime, Inc. (NYSE MKT: BTX) family of companies to begin trading publicly, following BioTime’s distribution of OncoCyte common stock to BioTime shareholders.
